Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026)

Janux Therapeutics (JANX) posted quarterly EBITDA Margin of 916.5% for Q1 2026, down 159.99% quarter-over-quarter from 352.51% in Q3 2025.

Janux Therapeutics (JANX) EBITDA Margin (2021 - 2026) Analysis & Trends

Janux Therapeutics (JANX) has reported EBITDA Margin for 6 consecutive years, with 916.5% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 916.5%; the TTM figure through Mar 2026 stood at 1143.11% (up 7351.0% YoY), while the FY2025 annual figure was 1576.67%, down 64309.0% from the prior year.
EBITDA Margin eased to 916.5% in Q1 2026 per JANX's latest filing, from 352.51% in the prior quarter.
Across five years, EBITDA Margin topped out at 155.36% in Q2 2024 and bottomed at 8164.46% in Q3 2024.
Historically, EBITDA Margin has averaged 1434.96% across 5 years, with a median of 852.23% in 2022.
Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 753622 bps — and 2025, when it soared 781195 bps.
Janux Therapeutics' EBITDA Margin stood at 642.04% in 2022, then slipped by 2 bps to 655.71% in 2023, then slumped by 1145 bps to 8164.46% in 2024, then soared by 96 bps to 352.51% in 2025, then slumped by 160 bps to 916.5% in 2026.
Business Quant data shows JANX's EBITDA Margin at 916.5% in Q1 2026, 352.51% in Q3 2025, and 8164.46% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Janux Therapeutics	984.58 Mn	984.58 Mn	-	-308.66%

Download Data